Loading news...
A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test's consistent clinical performance across nodule sizes and patient populations A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test's consistent clinical performance across nodule sizes and patient populations
The mean of analysts' price targets for Biodesix (BDSX) points to an 86.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month price objective among
The mean of analysts' price targets for Biodesix (BDSX) points to an 111.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $1.2 per share a year ago.
Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo.
LOUISVILLE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team will participate in two upcoming investor conferences:
LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 after the close of trading on Thursday, February 26. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) saw a significant growth in short interest in January. As of January 15th, there was short interest totaling 483,591 shares, a growth of 499.1% from the December 31st total of 80,722 shares. Based on an average trading volume of 7,865,756 shares, the short-interest ratio is presently 0.1 days.
Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo.
CochLear (OTCMKTS:CHEOY - Get Free Report) and Biodesix (NASDAQ: BDSX - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk. Earnings and Valuation This table compares CochLear and Biodesix"s top-line
The mean of analysts' price targets for Biodesix (BDSX) points to a 325.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings.
Biodesix, Inc. (BDSX) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.6. This compares to a loss of $1.4 per share a year ago.
Biodesix, Inc. ( BDSX ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Scott Hutton - President, CEO & Director Robin Cowie - CFO, Secretary & Treasurer Conference Call Participants Christopher Brinzey - Westwicke Partners, LLC Margarate Boeye - William Blair & Company L.L.C., Research Division Alexander Vukasin - Canaccord Genuity Corp., Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division William Ruby - TD Cowen, Research Division Presentation Operator " Christopher Brinzey Westwicke Partners, LLC " Scott Hutton President, CEO & Director " Robin Cowie CFO, Secretary & Treasurer " Margarate Boeye William Blair & Company L.L.C.
Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo.